5.22

4.40% -0.24

Rani Therapeutics Holdings Inc (RANI)

Overview News Price History Option Chain Financials Discussions Forecast

Rani Therapeutics Holdings Inc stock is currently priced at $5.22, with a 24-hour trading volume of 114.40K. It has seen a -4.40% decreased in the last 24 hours and a -33.50% declined in the past month. The chart indicates a potential bearish trend, as the stock is below the $5.51 pivot point. If it approaches the $5.17 support level, significant changes may occur.

Previous Close:

$5.46

Open:

$5.52

24h Volume:

114.40K

Market Cap:

$137.31M

Revenue:

$3.04M

Net Income/Loss:

$-33.97M

P/E Ratio:

-3.7826

EPS:

-1.38

Net Cash Flow:

$-52.47M

1W Performance:

-17.27%

1M Performance:

-33.50%

6M Performance:

+159.70%

1Y Performance:

+13.97%

1D Range:

$5.01

$5.735

52W Range:

$1.82

$8.75

Rani Therapeutics Holdings Inc Stock (RANI) Company Profile

Name

Rani Therapeutics Holdings Inc

Sector

Healthcare (1209)

Industry

Biotechnology (699)

Phone

408 457 3700

Address

2051 Ringwood Avenue, San Jose

Employee

Twitter

Next Earnings Date

2024-05-29

Latest SEC Filings

RANI's Discussions on Twitter

Rani Therapeutics Holdings Inc Stock (RANI) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-17-23	Resumed	BTIG Research	Buy
Oct-11-22	Initiated	UBS	Buy
Jul-27-22	Initiated	H.C. Wainwright	Buy
Jun-13-22	Initiated	Wedbush	Outperform

Rani Therapeutics Holdings Inc Stock (RANI) Latest News

Rani Therapeutics to Participate in May Investor Conferences - WICZ

WICZ

Rani Therapeutics to Participate in May Investor Conferences

GlobeNewswire Inc.

Research Analysts Issue Forecasts for Rani Therapeutics Holdings, Inc.'s FY2026 Earnings (NASDAQ:RANI) - MarketBeat

MarketBeat

Rani Therapeutics (NASDAQ:RANI) Price Target Raised to $14.00 at BTIG Research - Defense World

Defense World

Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Short Interest Down 27.9% in April - MarketBeat

MarketBeat

Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Receives $12.20 Consensus PT from Analysts - MarketBeat

MarketBeat

Rani Therapeutics Holdings Inc Stock (RANI) Financials Data

Rani Therapeutics Holdings Inc (RANI) Revenue 2024

RANI reported a revenue (TTM) of $3.04 million for the quarter ending June 30, 2021.

Rani Therapeutics Holdings Inc (RANI) Net Income 2024

RANI net income (TTM) was -$33.97 million for the quarter ending December 31, 2023, a -11.06% decrease year-over-year.

Rani Therapeutics Holdings Inc (RANI) Cash Flow 2024

RANI recorded a free cash flow (TTM) of -$52.47 million for the quarter ending December 31, 2023, a -9.00% decrease year-over-year.

Rani Therapeutics Holdings Inc (RANI) Earnings per Share 2024

RANI earnings per share (TTM) was -$1.33 for the quarter ending December 31, 2023, a -3.91% decline year-over-year.

Rani Therapeutics Holdings Inc Stock (RANI) Insider Trading

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total
Imran Talat	Chief Executive Officer	Dec 04 '23	Buy	2.57	5,000	12,850	474,455
Imran Talat	Chief Executive Officer	Nov 29 '23	Buy	2.05	20,000	41,000	469,455
South Cone Investments Limited	10% Owner	Nov 24 '23	Buy	2.01	5,265,165	10,582,982	12,131,554
Quiroga Cortes Isidoro Alfonso	10% Owner	Nov 24 '23	Sale	2.01	5,265,165	10,582,982	8,400
BUTEL JEAN LUC	Director	Nov 17 '23	Buy	2.03	50,500	102,495	50,500
Nanavaty Maulik	Director	Nov 16 '23	Buy	1.98	500	990	500
Imran Talat	Chief Executive Officer	Nov 07 '23	Buy	2.00	5,000	9,975	449,455

Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics. The company develops the RaniPill capsule, a platform that is intended to replace subcutaneous or IV injection of biologics with oral dosing. Its product pipeline includes RT-101, an octreotide, which has completed Phase I clinical trial for the treatment of neuroendocrine tumors and acromegaly; RT-105, an anti-TNF-alpha antibody to treat psoriatic arthritis; RT-102, a parathyroid hormone that is in preclinical studies for the treatment of osteoporosis; RT-109, a human growth hormone to treat growth hormone deficiency; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; RT-103, a glucagon-like peptide-1 mimetic to treat type 2 diabetes; and RT-106, a basal insulin for the treatment of type 2 diabetes. The company was incorporated in 2012 and is headquartered in San Jose, California.